NWR Communications reposted this
NTI164 has successfully reversed immune dysregulation in children with PANDAS/PANS, aligning with the significant clinical improvements seen in our Phase I/II trial at 12 weeks. NTI164 positively modifies immune cell function and gene translation, including the reversal of dysregulated pathways such as MECP2, associated with Rett Syndrome. This discovery highlights NTI164’s potential to normalise immune function and gene translation profiles, offering a promising disease-modifying treatment for PANDAS/PANS. Additional patent applications have been filed, with genomic analysis underway. Professor Russell Dale, Professor of Paediatric Neurology, University of Sydney and Children’s Hospital at Westmead and Co-Principal investigator of the NTIPANS1 trial said "My research group hypothesises PANDAS/PANS is the result of gene-environment (epigenetic) neuroimmune dysregulation leading to persistent or progressive neuroinflammation. Currently most patients are symptomatically managed, whereas NTI164’s anti-neuroinflammatory properties have now been shown to induce important epigenetic and proteomic changes in immune cells collected from patients at baseline (day zero) and after 12 weeks of treatment. This data is exciting as it demonstrates that the biological aspects of this debilitating condition can be modified by NTI164, including immune and epigenetic dysregulation, improving overall health and functional outcomes of children with PANDAS/PANS. We eagerly await further genomic analysis from these same patients.” Read the full ASX Announcement here: https://lnkd.in/guG3kgfa #NTI164 #PANDAS #PANS #Neurotech #NTI #Biotech #ClinicalTrials #ImmuneDysregulation #GeneTranslation #RettSyndrome #PediatricHealth #PharmaInnovation #ASX #OrphanDrugs #Proteomics #GenomicAnalysis #Healthcare Ontario Rett Syndrome Association PANDAS Network Official- PANS PANDAS UK PANDAS PPN @pansaustralia @PANDASPANSON @PANDASPPN @PANDASnetwork @PANSPANDASUK
